A clinical case of 3-year highly efficient pembrolizamable therapy of metasatic lung adenocarcinoma

Медицинский совет

K. K. Laktionov¹  K. A. Sarantseva¹  K. P. Laktionov¹  E. V. Reutova¹  D. I. Yudin¹  V. V. Breder¹ 

[1] N.N. Blokhin Russian Cancer Research Centre of the Ministry of Health of Russia;

关键词: pemribrolizumab;    non-small cell lung cancer;    pd-1;    pd-l1;   

DOI  :  10.21518/2079-701X-2018-10-9-10

来源: DOAJ

【 摘 要 】

Immunotherapy presents a new promising approach to the treatment of disseminated lung cancer. Pemriblisumab (Kitruda®) is one of the antiPD-1 drugs registered in Russia, which is used in both the secondand, in the event of high-level PD-L1 expression (≥50%), the first-line therapy. This paper presents a clinical observation of a highly efficient pemribrolizumab treatment of a patient with metastatic adenocarcinoma.

【 授权许可】

Unknown